Swiss Medica, Inc.

Swiss Medica, Inc.

May 25, 2005 06:00 ET

Swiss Medica, Inc.: Large U.S. National Pharmacy Chain Purchase Order for O24 Pain Neutralizer Product Boosts Total Store Count Above 13,000 Level

TORONTO, ONTARIO--(CCNMatthews - May 25, 2005) - Swiss Medica, Inc. (OTCBB:SWME), is pleased to announce that purchase orders from a large U.S. national pharmacy chain and a dominant U.S. regional pharmacy chain have increased coverage for the O24 Pain Neutralizer product to more than 13,000 stores, nearly 70 percent of which are in the United States.

"We are delighted that excitement is growing for our flagship, patented O24 Pain Relief product," said Tom Quinn, Swiss Medica's Executive Vice President. "We surpassed our store guidance for Q2, sales are approaching US$1 million for the first half of Q2 (April 1 to May 20), and year-to-date sales have surpassed US$2 million. O24 product has been shipped to the national U.S. pharmacy chain and will be available in June 2005 for the first time in major markets such as New England, the Carolinas, Texas, and Florida."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at, and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMSEscape which holds US Patent #'s 5760014 and 5612320. PMSEscape is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information